| Advancing Care in MASLD Programme | Time (SGT) |
|---|---|
| Chairs: Dr. Mark Muthiah & Prof. Hirokazu Takahashi | |
| Welcome Address – Prof. Arun Sanyal, USAView Bio, Dr. Mark Muthiah, SingaporeView Bio |
|
| Is MASLD in lean patients the same disease as in overweight and obese individuals? A clinical viewpoint – Prof. Vincent Wong, Hong Kong View Bio |
|
| Is MASLD in lean patients the same disease as in overweight and obese individuals? A pathobiological viewpoint – Prof. Sven Francque, Belgium View Bio |
|
| Similarities and differences between MetALD and MASLD – Prof. Ajay Duseja, India View Bio |
|
| Specific aetiology SLD in the Asian context – Dr. Daniel Huang Qingyao, Singapore View Bio |
|
| Combined Q&A | |
| Tea Break | |
| Chairs: Dr. Daniel Huang & Prof. Ming-Hua Zheng | |
| Interpreting NIT data: Lessons from NIMBLE and LITMUS – Prof. Arun Sanyal, USA View Bio |
|
| Intelligent use of NIT’s in clinical practice – moving forward and back from primary care – Prof. Chan Wah Kheong, Malaysia View Bio |
|
| A patient centric view of risk assessment: balancing competing risks – Dr. Mark Muthiah, Singapore View Bio |
|
| Artificial Intelligence in Liver Histology: Driving Development of MASLD Therapeutics – Dr. Dean Tai, Singapore View Bio |
|
| Combined Q&A | |
| UITC & ECHOSENS Lunch Symposium | |
| Asia Perspective on Fatty Liver Disease – Dr. George Goh, Singapore View Bio |
|
| Optimizing VCTETM assessment of MASLD – Prof. Vincent Wong, Hong Kong View Bio |
|
| Q&A Session | |
| FibroScan® 630 Expert SSM Demo Session | |
| Chairs: Dr. Edhel Tripon & Dr. Anand Kulkarni | |
| Debate: Will incretin-based obesity treatment solve the MASLD epidemic? – Yes: Dr. Jiangao Fan, China View Bio – No: Prof. Vincent Wong, Hong Kong View Bio |
|
| An oasis in the desert: Understanding the THRß _pathway and its agonism in MASLD – Prof. Paul M. Yen, Singapore View Bio |
|
| Future of FGF21 in treatment of MASLD – Prof. Arun Sanyal, USA View Bio |
|
| Future of PPAR in treatment of MASLD – Prof. Sven Francque, Belgium View Bio |
|
| Can data for bariatric surgery be extrapolated to endobariatrics for MASLD? – Dr. George Goh, Singapore View Bio |
|
| Combined Q&A | |
| Tea Break | |
| Chairs: Prof. Ajay Duseja & Prof. Phunchai Charatcharoenwitthaya | |
| State of the art: Why are we not making progress with cirrhotic MASH patients? – Prof. Arun Sanyal, USA View Bio |
|
| Special considerations in managing the decompensated MASH cirrhotic patient –Dr. Mark Muthiah, Singapore View Bio, |
|
| Case based discussion
– Moderators:
– Panel Speakers: |
|
| Combined Q&A | |
| Closing: National health policy for MASLD Prof. Dan Yock Young,Singapore View Bio |
|
